Denied Keytruda? You Still Have Options.
Keytruda (pembrolizumab) is an immunotherapy approved for more than 20 cancer types — but a denial can stop you cold, especially when time matters. Insurers often deny Keytruda when prior authorization wasn't completed, when the requested use falls outside the plan's covered indications (even if your oncologist has strong clinical reasons), or when specific biomarker testing results required by the plan are missing from the file. These are solvable problems, even when the denial feels final.
Option 1: Appeal Your Denial
In oncology, appeals move fast and they matter. Your oncologist's letter of medical necessity — including your cancer type, biomarker results, treatment history, and why Keytruda is the appropriate choice — is the cornerstone of a strong appeal. Some cancer denials also qualify for expedited review. Ellen can help you draft your appeal letter.
Option 2: Explore Clinical Trials
Pembrolizumab is one of the most studied cancer drugs in the world, and clinical trials studying Keytruda alone or in combination with other treatments are enrolling across dozens of cancer types right now. These trials may give you access to Keytruda at no cost while contributing to research that helps future patients. Search ClinicalTrials.gov for "pembrolizumab" plus your cancer type to see what's currently available near you.
Option 3: Patient Assistance Programs
Merck, Keytruda's manufacturer, offers the Merck Access Program, which includes financial assistance for eligible individuals. The Patient Advocate Foundation (patientadvocate.org) and CancerCare (cancercare.org) provide additional support, including case management for people navigating oncology drug denials.
For a complete guide to Keytruda financial assistance — including copay cards, free drug programs, and independent foundations — see our financial assistance page for Keytruda.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Why was Keytruda denied?
Keytruda denials often come down to a few specific issues: the indication (your cancer type and stage) doesn't match what the plan covers, required biomarker testing results weren't included in the prior authorization submission, or the requested use is for a purpose the FDA has approved but the plan has separately excluded. In some cases, the insurer wants additional clinical documentation before agreeing to cover such a high-cost therapy. Your denial letter will identify the specific reason.
Can I get Keytruda through a clinical trial?
Yes — this is a realistic path for many people. Pembrolizumab is one of the most actively studied cancer drugs, and sponsored trials may provide it at no cost to eligible participants. Trials may study Keytruda as a standalone therapy, in combination with chemotherapy, or alongside other immunotherapy agents. Your oncologist can help you evaluate which trials might fit your diagnosis and health status. You can also browse at ClinicalTrials.gov.
How long does a Keytruda appeal take?
For urgent cancer situations, appeals can move on an expedited timeline — as little as 72 hours when your doctor documents medical urgency. Standard appeals typically take up to 30 days. If your plan's internal appeal is denied, you can request an independent external review, usually resolved within 45 days or fewer. In cancer, urgency matters — document it clearly with your oncologist. Talk to your doctor before making any decisions about your treatment.